Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/223123
Title: Redefiniendo la retirada de omalizumab en pacientes con urticaria crónica espontánea: el valor de la optimización y de los biomarcadores de recurrencia
Author: Ceravalls Sanchez, Joan
Giménez Arnau, Ana M.
Expósito Serrano, Vicente
Fernández Chico, Natalia
Lara Moya, Aida
Bielsa Marsol, Isabel
Ribó González, Paula
Mascaró Hereza, Berta
Bonfill Ortí, Montserrat
Spertino, Jorge Luis
Serra Baldrich, Esther
Baliu Piqué, Carola
Melé Ninot, Gemma
Keywords: Urticària
Antihistamínics
Urticaria
Antihistamines
Issue Date: 20-May-2025
Publisher: Elsevier BV
Abstract: Background: Patients with chronic spontaneous urticaria frequently relapse after discontinuing omalizumab and require its reintroduction. Although prior optimization might reduce recurrences, there is scarce evidence on this issue. Moreover, predictors of relapse have been identified in non-optimized patients before suspension. Methods: We conducted a multicenter retrospective study with patients who discontinued omalizumab after optimization with a 12-month follow-up. Univariate and multivariate (tree classification method and Cox regression) analyses were performed. Results: A total of 131 patients were included, 32.8% of whom relapsed after 12 months. Relapsed patients had longer disease duration (24.00 vs 11.00 months; p = 0.032), quicker response to standard dosage (1.00 vs. 3.00 months; p = 0.014), fewer complete responses pre-optimization (83.70% vs 95.50%; p = 0.023), and shorter treatment duration at 300 mg/4 weeks (6 vs 7 months; p = 0.035). Multivariate analysis revealed that patients with elevated baseline C-reactive protein (CRP) and low total immunoglobulin E (IgE) who underwent prolonged treatment were more likely to maintain a sustained remission at 12 months. Conclusion: Optimization seems to reduce the relapse rate after discontinuation. The most relevant factors for recurrence are associated with the duration of treatment at different doses of omalizumab, along with the baseline CRP and total IgE levels. To minimize relapse after suspension, a 12-month treatment regimen at 300 mg/4 weeks followed by an 18-month dose tapering is proposed. (c) 2025 AEDV. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Note: Reproducció del document publicat a: https://doi.org/10.1016/j.ad.2025.05.004
It is part of: Actas Dermo-Sifiliográficas, 2025, vol. 116, num. 7, p. T675-T683
URI: https://hdl.handle.net/2445/223123
Related resource: https://doi.org/10.1016/j.ad.2025.05.004
ISSN: 1578-2190
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
1-s2.0-S0001731025003035-main.pdf1.03 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons